Abstract
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis and deeply affects the life of people. Therefore, the earlier diagnosis and better treatments are urgently needed. In recent years, the proteomic technologies are well established and growing rapidly and have been widely applied in clinical applications, especially in pancreatic cancer research. In this paper, we attempt to discuss the development of current proteomic technologies and the application of proteomics to the field of pancreatic cancer research. This will explore the potential perspective in revealing pathogenesis, making the diagnosis earlier and treatment.
Highlights
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis; the present treatments are incapable of producing a desired effect
We provide an overview of recent findings in proteomics of pancreatic cancer
The rapid development of proteomics was made possible by the progress in analytical instrumentation, especially in mass spectrometry, and it is increasingly becoming the foundation in leading scientific workgroups and in clinical research labs
Summary
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis; the present treatments are incapable of producing a desired effect. The patients generally die within six months after diagnosis, and the overall five-year survival rate is less than 5% [1]. Its incidence is increasing in China and other countries. The earlier diagnosis and better treatments are urgently needed. The development of quantitative proteomics technology has stimulated considerable interest in applying the technology for clinical applications, such as revealing pathogenesis, making the diagnosis earlier, and treatment. We provide an overview of recent findings in proteomics of pancreatic cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
